Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ZNTL

Zentalis Pharmaceuticals Inc

Dec 01 • 04:00PM ET

11.34

Dollar change +0.09
Percentage change 0.80	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-4.63	Insider Own	10.21%	Shs Outstand	70.77M	Perf Week	4.52%
Market Cap	802.53M	Forward P/E	-	EPS next Y	-3.76	Insider Trans	192.44%	Shs Float	63.54M	Perf Month	-30.64%
Income	-286.25M	PEG	-	EPS next Q	-0.89	Inst Own	110.07%	Short Float / Ratio	16.65% / 10.09	Perf Quarter	-58.22%
Sales	0.00M	P/S	-	EPS this Y	-0.14%	Inst Trans	-1.11%	Short Interest	10.58M	Perf Half Y	-56.83%
Book/sh	6.82	P/B	1.66	EPS next Y	16.09%	ROA	-51.35%	Target Price	34.10	Perf Year	-48.73%
Cash/sh	7.30	P/C	1.55	EPS next 5Y	-	ROE	-62.89%	52W Range	9.56 - 31.46	Perf YTD	-43.69%
Dividend	-	P/FCF	-	EPS past 5Y	-66.20%	ROI	-54.52%	52W High	-63.95%	Beta	1.58
Dividend %	-	Quick Ratio	8.97	Sales past 5Y	-25.00%	Gross Margin	-	52W Low	18.62%	ATR	0.90
Employees	156	Current Ratio	8.97	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	39.36	Volatility	5.77% 9.24%
Optionable	Yes	Debt/Eq	0.09	EPS Q/Q	17.88%	Profit Margin	-	Rel Volume	0.53	Prev Close	11.25
Shortable	Yes	LT Debt/Eq	0.09	Earnings	Nov 06 BMO	Payout	-	Avg Volume	1.05M	Price	11.34
Recom	1.36	SMA20	-0.71%	SMA50	-28.21%	SMA200	-47.48%	Volume	558,717	Change	0.80%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-08-23	Downgrade	Wedbush	Outperform → Neutral	$38 → $12
Nov-07-23	Downgrade	Leerink Partners	Outperform → Market Perform	$15
Jul-12-22	Initiated	Cowen	Outperform
Apr-06-22	Initiated	Wells Fargo	Overweight	$67
Oct-07-21	Resumed	Jefferies	Buy	$120
Sep-30-21	Initiated	Stifel	Buy	$84
Sep-29-21	Initiated	Oppenheimer	Outperform	$90
May-21-21	Initiated	UBS	Buy	$91
Jan-20-21	Initiated	Wedbush	Outperform	$65
Sep-29-20	Initiated	Cantor Fitzgerald	Overweight	$44
Aug-27-20	Initiated	H.C. Wainwright	Buy	$43
Apr-28-20	Initiated	SVB Leerink	Outperform	$45
Apr-28-20	Initiated	Morgan Stanley	Overweight	$45
Apr-28-20	Initiated	Jefferies	Buy	$41
Apr-28-20	Initiated	Guggenheim	Buy	$45

Show Previous Ratings

Dec-01-23 05:39PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-13-23 09:03PM	Director David Johnson's Strategic Purchase of Zentalis Pharmaceuticals Inc Shares (GuruFocus.com)
Nov-09-23 07:00AM	Zentalis to Participate in Investor Call Focused on Ovarian Cancer with Gynecologic Oncology Key Opinion Leader Joyce F. Liu, M.D., MPH, Hosted by TD Cowen (GlobeNewswire)
Nov-06-23 07:13PM	Zentalis Pharmaceuticals Inc (ZNTL) Reports Q3 2023 Financial Results and Operational Updates (GuruFocus.com) -30.20%
07:18AM	Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates (GlobeNewswire)
04:52PM	Loading…
Nov-01-23 04:52PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-07-23 05:00AM	Insider Sell: Chief Medical Officer Carrie Brownstein Sells 10,628 Shares of Zentalis ... (GuruFocus.com)
Oct-02-23 04:27PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-14-23 01:02AM	Director Jan Skvarka Sells 5,000 Shares of Zentalis Pharmaceuticals Inc (ZNTL) (GuruFocus.com)
Sep-06-23 07:00AM	Zentalis Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Sep-01-23 04:37PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-09-23 07:00AM	Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates (GlobeNewswire)
Aug-01-23 04:28PM	Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Zentalis Pharmaceuticals Appoints Kimberly Freeman as Chief Strategy Officer (GlobeNewswire)
Jun-15-23 06:01AM	Zentalis Pharmaceuticals Announces Pricing of Underwritten Offering of Common Stock (GlobeNewswire) +12.67%
06:00AM	Loading…
Jun-06-23 06:00AM	Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing (GlobeNewswire)
Jun-02-23 02:34PM	Why Shares of Zentalis Pharmaceuticals Dropped This Week (Motley Fool)
May-26-23 12:33PM	Wells Fargo Predicts up to 70% Rally for These 2 Stocks Heres Why They Have Solid Upside (TipRanks) +10.64%
10:53AM	Zentalis Gears Up for Phase 3 Study of Azenosertib after Positive Phase 1b Outcomes (Benzinga)
May-25-23 05:38PM	Zentalis Announces Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy at the 2023 ASCO Annual Meeting (GlobeNewswire)
May-23-23 07:00AM	Zentalis to Host Investor Call to Provide Clinical Update with Safety, Pharmacology, and Efficacy Results for Azenosertib Monotherapy and Development Plans for Monotherapy and Chemotherapy Combinations (GlobeNewswire)
May-12-23 09:55AM	Wall Street Analysts Believe Zentalis Pharmaceuticals, Inc. (ZNTL) Could Rally 95.67%: Here's is How to Trade (Zacks)
May-10-23 07:00AM	Zentalis Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates (GlobeNewswire) +6.93%
Apr-26-23 10:00AM	Zentalis to present positive clinical data in ovarian cancer combining azenosertib and chemotherapy, including clinical support for Cyclin E1 expression as predictive marker for clinical benefit from azenosertib at the 2023 ASCO Annual Meeting (GlobeNewswire)
Apr-17-23 09:00AM	Zentalis Announces Preclinical Data Supporting Cyclin E1 As A Predictive Marker For Azenosertib Treatment At AACR Annual Meeting 2023 (GlobeNewswire) +7.51%
Mar-01-23 07:00AM	Zentalis Pharmaceuticals Reports Full Year 2022 Financial Results and Operational Updates (GlobeNewswire)
Feb-13-23 07:00AM	Zentalis Pharmaceuticals Appoints Dr. Iris Roth as Chief Operating Officer (GlobeNewswire)
Feb-01-23 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:01AM	Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Jan-17-23 09:18AM	We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely (Simply Wall St.)
05:00PM	Loading…
Jan-03-23 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-08-22 09:55AM	Can Zentalis Pharmaceuticals, Inc. (ZNTL) Climb 170% to Reach the Level Wall Street Analysts Expect? (Zacks)
Dec-01-22 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-09-22 07:00AM	Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates (GlobeNewswire) -21.98%
Nov-08-22 07:01AM	Zentalis Pharmaceuticals to Participate in the Stifel 2022 Healthcare Conference (GlobeNewswire)
Nov-01-22 05:38PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-24-22 07:00AM	Zentalis Pharmaceuticals Announces First ZN-c3 Clinical Development Collaboration with Pfizer (GlobeNewswire)
Oct-17-22 07:00AM	Zentalis Pharmaceuticals Appoints Dr. Mark Lackner as Chief Translational Officer, Head of Biomarker Strategy (GlobeNewswire)
Oct-03-22 05:32PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-27-22 04:01PM	Zentalis Pharmaceuticals Promotes Co-Founder Kevin Bunker, Ph.D. to Chief Scientific Officer (GlobeNewswire)
Sep-19-22 07:00AM	Zentalis Pharmaceuticals Appoints Dr. Carrie Brownstein as Chief Medical Officer (GlobeNewswire)
Sep-12-22 07:00AM	Zentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directors (GlobeNewswire)
Sep-01-22 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-31-22 07:00AM	Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-26-22 12:00PM	Zentalis Pharmaceuticals, Inc. (ZNTL) Upgraded to Buy: Here's What You Should Know (Zacks)
Aug-16-22 09:55AM	Does Zentalis Pharmaceuticals, Inc. (ZNTL) Have the Potential to Rally 129% as Wall Street Analysts Expect? (Zacks) -6.12%
Aug-10-22 04:39PM	This Analyst Says Zentalis' Increased Focus On WEE1 Program Is 'Prudent', Slashes Price Target By 37% (Benzinga)
10:01AM	We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely (Simply Wall St.)
08:40AM	Why Zentalis Pharmaceuticals (ZNTL) Might Surprise This Earnings Season (Zacks)
Aug-09-22 04:01PM	Zentalis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update (GlobeNewswire)
Aug-03-22 07:00AM	Zentalis Pharmaceuticals to Participate in the Wedbush PacGrow Healthcare Conference (GlobeNewswire)
Aug-01-22 05:10PM	Zentalis Pharmaceuticals, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-27-22 07:00AM	Zentalis Pharmaceuticals Appoints Andrea Paul as General Counsel and Corporate Secretary (GlobeNewswire)
Jun-14-22 09:10AM	Billionaire Mario Gabelli is Dumping These 10 Stocks in 2022 (Insider Monkey)
Jun-01-22 07:00AM	Zentalis Pharmaceuticals to Participate in the Jefferies Healthcare Conference (GlobeNewswire)
May-31-22 07:00AM	Zentalis Pharmaceuticals Promotes Cofounder Cam Gallagher to President (GlobeNewswire)
May-26-22 09:48AM	Mario Gabelli is Selling These 15 Stocks in 2022 (Insider Monkey) +6.43%
May-21-22 09:48AM	What Percentage Of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Do Insiders Own? (Simply Wall St.)
May-18-22 04:01PM	Zentalis Pharmaceuticals Announces Closing of Underwritten Offering of Common Stock (GlobeNewswire) -9.24%
May-16-22 07:28AM	Zentalis Pharmaceuticals Announces Pricing of Underwritten Offering of Common Stock (GlobeNewswire) +18.90%
07:00AM	Zentalis Pharmaceuticals Appoints Oncology Clinical Development Veteran Dr. Kimberly Blackwell as Chief Executive Officer (GlobeNewswire)
May-05-22 07:00AM	Zentalis Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update (GlobeNewswire) -6.71%
Apr-27-22 10:17AM	Pfizer Injects $25M Via Equity In Zentalis Pharma (Benzinga) +11.77%
07:00AM	Zentalis Pharmaceuticals Announces $25 Million Equity Investment from Pfizer (GlobeNewswire)
Apr-19-22 09:35AM	Here's Why Zentalis Pharmaceuticals, Inc. (ZNTL) is Poised for a Turnaround After Losing 50% in 4 Weeks (Zacks)
Apr-11-22 04:01PM	Zentalis Pharmaceuticals Announces Overview of Clinical and Preclinical Data Presented at AACR (GlobeNewswire) -8.10%
07:22AM	Zentalis Pharma Posts Initial Clinical Data On Its Wee1 Inhibitor In Ovarian Cancer (Benzinga)
Apr-08-22 01:00PM	Zentalis Pharmaceuticals Announces Positive Initial Clinical Data on ZN-c3, its Wee1 Inhibitor, in Patients with Advanced Ovarian Cancer at AACR (GlobeNewswire) -30.02%
Mar-29-22 07:00AM	Zentalis Pharmaceuticals and Caris Life Sciences Announce Strategic Collaboration to Support Clinical Studies, Initially Focused on the Wee1 Inhibitor ZN-c3 (GlobeNewswire) +6.54%
Mar-22-22 07:00AM	Zentalis Pharmaceuticals Announces First Patient Dosed in the Potentially Registrational Phase 1/2 Study of BCL-2 inhibitor ZN-d5 in Patients with Relapsed or Refractory Light Chain (AL) Amyloidosis (GlobeNewswire)
Mar-09-22 04:01PM	Zentalis Pharmaceuticals to Present at the Oppenheimer Annual Healthcare Conference (GlobeNewswire) +9.66%
Mar-08-22 04:30PM	Zentalis Pharmaceuticals to Present New Clinical and Preclinical Data at the AACR Annual Meeting 2022 (GlobeNewswire)
Feb-24-22 07:00AM	Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update (GlobeNewswire) +6.73%
Feb-03-22 07:00AM	Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Dec-22-21 10:15AM	Zentalis Pharmaceuticals Inc (ZNTL) COO Kevin D. Bunker Sold $792,400 of Shares (GuruFocus.com)
Dec-21-21 12:03PM	We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely (Simply Wall St.)
Dec-14-21 11:15AM	Zentalis Pharmaceuticals Inc (ZNTL) COO Kevin D. Bunker Sold $717,100 of Shares (GuruFocus.com)
Dec-02-21 07:00AM	Zentalis Pharmaceuticals to Host Virtual Research and Development (R&D) Day on December 16, 2021 (GlobeNewswire) +6.51%
Nov-17-21 11:35AM	Zentalis Pharmaceuticals Insider Sold Over $750K In Company Stock (Benzinga)
07:00AM	Zentalis Pharmaceuticals Announces Fast Track Designation Granted by the U.S. FDA to ZN-c3 for the Treatment of Uterine Serous Carcinoma (GlobeNewswire)
Nov-10-21 07:00AM	Zentalis Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Update (GlobeNewswire)
Nov-09-21 07:00AM	Zentalis Pharmaceuticals to Present at Two Upcoming Investor Conferences (GlobeNewswire)
Nov-08-21 10:07AM	Director Of Zentalis Pharmaceuticals Makes $830K Sale (Benzinga)
Nov-03-21 11:26AM	Zentalis Pharmaceuticals Insider Trades $1.7M In Company Stock (Benzinga)
Oct-25-21 12:04PM	Hedge Funds Are Piling Into Zentalis Pharmaceuticals, Inc. (ZNTL) (Insider Monkey)
Oct-05-21 11:28AM	Zentalis Pharmaceuticals Insider Trades $1.8M In Company Stock (Benzinga)
Sep-13-21 07:00AM	Zentalis Pharmaceuticals Announces First Patient Dosed in the Phase 1/2 Study of ZN-c3 in Combination with Gemcitabine in Patients with Osteosarcoma (GlobeNewswire)
Sep-09-21 07:00AM	Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2021 (GlobeNewswire)
Sep-02-21 07:00AM	Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Sep-01-21 07:00AM	Zentalis Pharmaceuticals Announces Publication in the Journal of Medicinal Chemistry Highlighting the Discovery of its WEE1 Inhibitor Candidate ZN-c3 (GlobeNewswire)
Aug-12-21 07:00AM	Zentalis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update (GlobeNewswire)
Aug-04-21 07:00AM	Zentalis Pharmaceuticals to Participate in the Wedbush PacGrow Healthcare Virtual Conference (GlobeNewswire)
Aug-02-21 07:30AM	Zentalis Pharmaceuticals Announces First Patient Dosed in Potentially Registrational Phase 2 Study of ZN-c3 in Patients with Uterine Serous Carcinoma (GlobeNewswire) -5.71%
07:00AM	Zentera Therapeutics Announces Closing of $75 Million Series B Financing (GlobeNewswire)
Jul-28-21 01:15PM	Is ZNTL Stock A Buy or Sell? (Insider Monkey)
Jul-01-21 04:01PM	Zentalis Pharmaceuticals Announces Closing of Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Jun-29-21 06:54AM	Zentalis Secures $150M In Equity Funding (Benzinga) +8.55%
Jun-28-21 09:09PM	Zentalis Pharmaceuticals Announces Pricing of Offering of Common Stock (GlobeNewswire)
04:18PM	Zentalis Pharmaceuticals Announces Proposed Public Offering of Common Stock (GlobeNewswire)
07:00AM	Zentalis Pharmaceuticals Announces Updates Across its Pipeline Including Promising New Interim Clinical Data on ZN-c3 (WEE1i) and ZN-c5 (SERD) and Two Potentially Registrational Trials for ZN-c3, with the First Trial Already Initiated (GlobeNewswire)

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin D. Bunker on December 23, 2014 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Blackwell Kimberly	Chief Executive Officer	Nov 13	Buy	10.29	5,000	51,448	254,800	Nov 13 05:24 PM
Johnson David Michael	Director	Nov 10	Buy	9.88	17,000	167,943	144,389	Nov 13 05:24 PM
Brownstein Carrie	Chief Medical Officer	Oct 04	Sale	19.50	10,628	207,298	105,685	Oct 06 07:19 PM
Bunker Kevin D.	Chief Scientific Officer	Oct 04	Sale	19.50	6,068	118,355	859,089	Oct 06 07:19 PM
Epperly Melissa B,	Chief Financial Officer	Oct 04	Sale	19.50	5,482	106,926	387,691	Oct 06 07:18 PM
Skvarka Jan	Director	Sep 11	Sale	25.05	5,000	125,238	47,970	Sep 13 04:11 PM
Matrix Capital Management Comp	10% Owner	Jun 20	Buy	22.66	4,760,000	107,861,600	13,959,973	Jun 20 04:30 PM
Gallagher Cam	President	May 31	Sale	26.27	27,768	729,506	463,502	May 31 09:10 PM
Bunker Kevin D.	Chief Scientific Officer	May 26	Sale	30.02	80,000	2,401,248	15,000	May 31 09:09 PM
Gallagher Cam	President	Feb 14	Sale	19.96	8,501	169,706	491,270	Feb 14 07:09 PM
Bunker Kevin D.	Chief Scientific Officer	Feb 14	Sale	19.98	6,500	129,873	865,157	Feb 14 07:07 PM
Epperly Melissa B,	Chief Financial Officer	Feb 14	Sale	19.98	5,227	104,411	392,048	Feb 14 07:10 PM
Bunker Kevin D.	Chief Scientific Officer	Feb 13	Sale	20.42	3,807	77,756	871,657	Feb 14 07:07 PM
Gallagher Cam	President	Feb 13	Sale	20.42	3,332	68,054	499,771	Feb 14 07:09 PM
Epperly Melissa B,	Chief Financial Officer	Feb 13	Sale	20.42	2,624	53,594	397,275	Feb 14 07:10 PM
Gallagher Cam	President	Feb 06	Sale	22.27	10,000	222,678	503,103	Feb 06 07:36 PM
Gallagher Cam	President	Jan 17	Sale	24.15	10,000	241,515	352,011	Jan 18 05:15 PM
Gallagher Cam	President	Jan 05	Sale	21.02	10,000	210,228	362,011	Jan 05 07:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ZNTL

Zentalis Pharmaceuticals Inc

Upgrade your FINVIZ experience